Acomplia zimulti generic name - rimonabant
October 13th, 2007 Acomplia also known as SR141716, Rimonabant, Riobant, Slimona, Rimoslim, and Zimulti is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite.
Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m^(2), or patients wih a BMI greater than 27 kg/m^(2) with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries.
How does it work?
Acomplia tablets contain the active ingredient rimonabant, which is a type of medicine called a cannabinoid-1 receptor antagonist. It is used to aid weight loss in people who are obese or overweight.
Rimonabant works by blocking receptors called cannabinoid-1 receptors (CB1). These are found in the brain, fat tissue, digestive system, liver and muscles.
The CB1 receptors are part of a system in the body called the endocannabinoid system. This system has only recently been discovered and explored. It is involved in regulating energy balance, sugar and fat metabolism and body weight.
The CB1 receptors found in a particular area of the brain called the mesolimbic system are involved in controlling our intake of highly palatable, sweet or fatty foods. Overactivation of the CB1 receptors is associated with increased appetite, cravings for food and fat build-up.
Rimonabant blocks CB1 receptors and so reduces cravings for these types of foods and helps decrease appetite and control hunger.
Rimonabant may also increase blood levels of “good fats” called HDL-cholesterol and reduce blood levels of “bad fats” called triglycerides. Read the rest of this entry »
